AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge
AstraZeneca has announced the findings of archaeological excavations on the Cambridge Biomedical Campus, which will be home to the company’s new, purpose-built global R&D centre and corporate headquarters from the end of 2016.
AstraZeneca collaborates with Inserm in type 2 diabetes and chronic kidney disease studies
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD). The aim of the collaboration is to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this…
AstraZeneca announces results of study into safety of diabetes therapies
AstraZeneca today announced results from an observational, retrospective study which found no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas.
AstraZeneca presents data demonstrating progress of diabetes portfolio
AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentation at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on 1 June 2015.
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015
AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
AstraZeneca & Lilly collaborate on Immuno-oncology clinical trial in solid tumours
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination…
AstraZeneca provides update on brodalumab development programme
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
AstraZeneca invests in new biologics manufacturing facility in Södertälje, Sweden
AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics.
AstraZeneca updates on immuno-oncology pipeline and combination treatments at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015. 61 scientific abstracts2 will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination…
AstraZeneca and MHI to screen 80,000 samples for cardiovascular and diabetes genetic traits
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes
AstraZeneca & Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab. To date, no companion diagnostic blood tests have been approved for use in asthma.
Mene Pangalos elected to the Fellowship of the Academy of Medical Sciences
IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK
US FDA grants Priority Review for potential new indication for BRILINTA
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack.
AstraZeneca collaborates with Celgene Corporation to develop PD-L1 inhibitor programme
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers.
AstraZeneca & Innate Pharma announce global co-development & commercialisation collaboration
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology.
AstraZeneca and Bina collaborate to deploy genomic management solution in R&D
AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme and to further develop the Bina Genomic Management Solution (GMS).
AstraZeneca announces latest data for investigational non-small cell lung cancer medicine
Late breaking data presented at the European Lung Cancer Congress 2015 shows delay in disease progression of over a year for AstraZeneca's investigational non-small cell lung cancer medicine AZD9291.
Selumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.
FDA Advisory Committee reviews SAVOR outcomes study results
FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® (saxagliptin) and KOMBIGLYZE® XR (saxagliptin and metformin HCI extended-release).
Tremelimumab granted Orphan Drug Designation by US FDA for malignant mesothelioma treatment
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the anti-CTLA-4 monoclonal antibody, tremelimumab, for the treatment of malignant mesothelioma.
AstraZeneca and PatientsLikeMe announce global research collaboration
A five-year agreement is focused on improving health outcomes for patients across AstraZeneca’s main therapy areas.
AstraZeneca showcases oncology science at American Association for Cancer Research AGM 2015
AstraZeneca will present new data at the American Association for Cancer Research (AACR) annual meeting in Philadelphia this weekend, demonstrating the strength and depth of its early stage oncology pipeline.
AstraZeneca joins Genomics England consortium
AstraZeneca today announced that it has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project.
AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.